Background Despite multiple available fixed-dose combinations (FDCs) of inhaled long-
acting β 2-agonists (LABAs) plus long-acting muscarinic antagonists (LAMAs) and LABAs …

Introduction Triple inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β 2-
agonist (ICS/LAMA/LABA) combination therapy is recommended for patients with chronic …

The purpose of this study was to systematically review the efficacy and safety of long-acting
β-agonist/long-acting muscarinic antagonist (LABA/LAMA) and LABA/inhaled corticosteroid …

Background Inhaled corticosteroid (ICS)/long-acting β 2-agonist (LABA) combination is
commonly prescribed to treat COPD; therefore, we performed a meta-analysis on the effect …

Introduction We performed a real-life retrospective analysis to assess the impact of long-
acting bronchodilator therapy and associated exposure to inhaled corticosteroids (ICS) on …

Background Researchers have yet to obtain conclusive evidence differentiating among fixed-
dose combinations (FDCs) of long-acting muscarinic antagonists (LAMAs) and long-acting β …

Background Long-acting β 2-agonists (LABAs) and long-acting muscarinic antagonists
(LAMAs) are recommended as initial maintenance treatments for COPD, with their …

Many clinicians initiate treatment of COPD by prescribing long-acting beta agonist/inhaled
corticosteroid fixed-dose combinations (LABA/ICS FDCs), despite the growing evidence …

Background: The recent approval of several fixed-dose combination long-acting β2-agonist
(LABA) and long-acting muscarinic antagonist (LAMA) products has increased the use of …

Background Triple therapy combinations of a long-acting muscarinic antagonist (LAMA), a
long-acting beta 2-agonist (LABA), and an inhaled corticosteroid (ICS) for COPD were …